Skip to main content
. 2019 Sep 4;28(2):264–273. doi: 10.1038/s41431-019-0501-7

Table 2.

CNV candidate genes for GSD

Gene ID N° GSD cases N° controls Case sex Chr CNV start (hg19) CNV end (hg19) Type Cohort
ALAS1 1 0 Male 3 52,082,780 53,128,685 Loss POPGEN
BDH1 1 0 Female 3 196979974 197340846 Gain SHIP-2
AGPAT9 1 0 Female 4 84,039,517 85,091,231 Gain ANCORA
PRKAA1, OXCT1 1 0 Female 5 37,623,393 42,403,769 Gain ANCORA
POR 1 0 Male 7 75,220,393 75,956,150 Gain POPGEN
AGPAT5 1 0 Male 8 6,254,942 6,661,675 Gain POPGEN
LYN 1 0 Male 8 56,753,726 57,051,296 Gain POPGEN
PLIN2 1 0 Female 9 19,031,461 19,226,776 Gain POPGEN
PDHX 1 0 Male 11 34,592,852 34,952,574 Gain POPGEN
GOLT1B 1 0 Female 12 20837585 21981183 Gain SHIP-2
HNF1A 1 0 Female 12 121,202,411 121,744,337 Gain POPGEN
RB1 1 0 Male 13 48646292 49269685 Loss SHIP-2
FECH, ATP8B1 2 0 Male, Female 18 55,206,938 55,465,080 Gain POPGEN
SULT2A1 1 0 Female 19 48,085,947 48,392,233 Gain POPGEN
RBL1 1 0 Female 20 35524811 35731498 Gain SHIP-2
PCK1 1 0 Male 20 55,665,634 56,143,223 Gain POPGEN
APOL1, APOL2 1 0 Male 22 36,556,147 36,749,312 Gain POPGEN
TBL1X 1 0 Female X 9,443,988 9,763,908 Gain ANCORA
PDHA1 1 0 Male X 18,662,632 19,449,407 Gain POPGEN
OCRL 1 0 Female X 113,759,647 150,222,670 Loss POPGEN